Thomas Catinazzo, who serves as the Chief Financial Officer at Relay Therapeutics, Inc. (NASDAQ: RLAY), completed a stock sale transaction on July 6, 2026. The executive disposed of 17,717 shares of the company's common equity during this period. The total value generated from the transaction reached $331,130. The shares were sold at prices ranging between $18.39 and $19.38, resulting in a weighted average sale price of $18.69 per share. This disposition was carried out under the framework of a Rule 10b5-1 trading plan, which Catinazzo established on October 30, 2025.
The timing of this insider sale coincides with RLAY trading near its 52-week high of $20.20. The stock has experienced a substantial 450% gain over the past year. Following the transaction, Catinazzo directly holds 159,744 shares of Relay Therapeutics common stock. This total includes 9,807 shares underlying restricted stock units. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Investors can access comprehensive valuation metrics and 16 additional ProTips on InvestingPro.
In broader corporate developments, Relay Therapeutics Inc. announced a $275 million stock offering. The offering involves pricing 22,916,667 shares at $12 each. This initiative aims to bolster the company's financial resources, excluding any additional shares the underwriters may purchase. On the clinical front, the company presented promising initial results from its Phase 2 ReInspire trial for zovegalisib, a drug targeting PIK3CA-driven vascular anomalies.
The trial data prompted several analyst firms to adjust their outlooks. H.C. Wainwright raised its price target for Relay Therapeutics to $28, maintaining a Buy rating. Similarly, Guggenheim increased its price target to $26, highlighting the drug's potential improvement over existing treatments and its favorable safety profile. Citizens also adjusted its price target to $21, acknowledging strong trial data, including a 60% volumetric response rate at 12 weeks. JPMorgan initiated coverage with an overweight rating, setting a price target of $28, citing zovegalisib as a potential multi-indication growth driver. These developments reflect a positive outlook from multiple analyst firms.
Current market data shows RLAY closing at 19.63, down 0.11 or -0.56%. After hours trading saw the stock at 19.18, down 0.45 or -2.29%. The stock has experienced significant volatility, with a 1-day, 1-week, 1-month, 6-month, 1-year, 5-year, and max chart available for analysis. The article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Is RLAY undervalued—or a trap? Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what RLAY is really worth. Get instant clarity on RLAY—plus thousands of other stocks—before the opportunity disappears. July Sale - 60% Off InvestingPro.